A targeted drug delivery device and system

Abstract

The present invention proposes a targeted drug delivery device, comprising: a drug storage bin (11), located inside the targeted drug delivery device; a drug channel (14), the drug channel (14) leading from the surface of the targeted drug delivery device to the drug storage bin (11), and a drug sustained-release element (13), which is located in the drug storage bin (11) and / or the drug channel (14), and is used to enable the drug in the drug storage bin (11) to be sustained-released through the drug channel (14). The present invention also proposes a targeted drug delivery system, which comprises the targeted drug delivery device and a navigation device. The present invention can accurately achieve targeted drug delivery, hierarchical regulation, high drug sustained-release stability, and controllable drug sustained-release flow.

Description

Technical Field

[0001] The present invention relates to a drug delivery device, and more particularly, to a targeted drug delivery device and system. Background Art

[0002] Targeted drug delivery is an ideal drug delivery method that can more accurately control the release of drugs to specific tissues, organs or cells, prolong the drug delivery process, and maintain the drug concentration in the target area for a long time. It has the advantages of low toxicity and high bioavailability. Existing targeted drug delivery usually involves the use of carriers, ligands or antibodies to deliver drugs locally to the gastrointestinal tract, or selectively concentrate and locate drugs in target tissues, target organs, target cells or intracellular structures through systemic blood circulation. However, the stability of targeted drug delivery in the prior art is poor, especially the stability of targeted preparations administered by intravenous injection in the blood. The drug may be circulated and transported to the whole body before reaching the target; secondly, a carrier can only target a specific targeting group. Therefore, targeted drug delivery is usually used in tumor treatment and is not widely applicable. Thirdly, the pharmacokinetic law of carrier targeted drug delivery in vivo also shows that the particle size and surface properties of the drug delivery system have a huge impact on the targeting of the targeted drug delivery system.

[0003] Implantable drug delivery system (IDDS) is a type of controlled drug release device that is surgically implanted into the body or subcutaneously or introduced into the subcutaneously through puncture. It is a long-term drug delivery system. It overcomes the shortcomings of traditional drug delivery methods during long-term drug delivery, can stably control the drug concentration in the target area or blood drug concentration for a long time, improve the bioavailability of the drug, thereby reducing the dosage and reducing side effects.

[0004] The current IDDS can be divided into two categories: uncontrollable and controllable. After being implanted in the body, uncontrollable IDDS will follow the established release mode to release drugs and cannot actively change the drug release state; controllable IDDS can modify the drug release mode according to actual needs after being implanted in the body. Most of the current controllable IDDS require batteries, circuits, etc. to provide energy, with complex structures and high costs. In addition, they are difficult to implant for long-term use due to the limitation of battery power.

[0005] CN201324434Y Chinese invention patent discloses an embedded rechargeable subcutaneous sustained-release drug delivery pump. Through the drug-carrying pump, the pressure generated by the elastic puncture membrane in the body can achieve continuous and slow drug delivery. Although the device can be buried subcutaneously and has good biocompatibility, the drug release method is continuous and slow drug release, and the drug cannot be stopped, such as intermittent drug delivery over a long period of time, so it cannot control drug release and has certain limitations.

[0006] The stability of targeted drug delivery in the prior art is poor; subcutaneous drug sustained-release devices are mostly continuous and slow drug release, which is not effective for certain drugs that require intermittent administration; most of the current controllable IDDS require batteries, circuits, etc. to provide energy, and are complex in structure, high in cost, and difficult to implant for long-term use due to battery power limitations. Therefore, it is necessary to develop a tissue repair system that can be implanted for a long time and has targeted sustained-release drug delivery, which can achieve controlled release of drugs over a long period of time, and needs to have good biocompatibility and will not induce inflammatory reactions in the body. At the same time, according to the controllability requirements, the drug release device needs to be able to facilitate continuous drug delivery and facilitate surgical navigation. Summary of the invention

[0007] In response to the problems in the background technology, the present invention proposes a targeted drug delivery device system, comprising: a drug storage chamber, located inside the targeted drug delivery device system; a drug channel, the drug channel leading from the surface of the targeted drug delivery device system to the drug storage chamber, and a drug sustained-release element, which is located in the drug storage chamber and / or the drug channel, and is used to enable the drug in the drug storage chamber to be sustained-released through the drug channel.

[0008] The present invention also provides a targeted drug delivery system, comprising:

[0009] The drug delivery device comprises: a drug storage bin located inside the targeted drug delivery device system; a drug channel, which leads from the surface of the targeted drug delivery device system to the drug storage bin; a drug sustained-release element, which is located inside the drug storage bin and / or the drug channel, and is used to enable the drug in the drug storage bin to be slowly released through the drug channel, wherein the drug delivery device further comprises: a navigation component channel, inside which a magnetic component is arranged;

[0010] The navigation device comprises: a navigation positioning channel, in which a magnet is arranged, and the magnet can be attracted to the magnetic component in the navigation component channel; a drug loading navigation channel, when the navigation device and the drug delivery device are attracted together, the drug loading navigation channel is connected with the drug channel of the drug delivery device.

[0011] An external magnetic navigation device can be used to navigate through the skin and enter the drug storage chamber to re-implant the drug, thereby achieving the purpose of long-term and multiple drug administration; the interaction between the internal static magnetic field and the external magnetic components can facilitate surgical navigation positioning and accelerate tissue repair.

[0012] The beneficial effects of the present invention are as follows: the device of the present invention breaks away from the existing idea of ​​targeted drug delivery, accurately realizes targeted drug delivery, graded regulation, high stability of drug sustained release, and controllable drug sustained release flow. In another embodiment, intermittent phased drug delivery can be achieved to fully ensure the drug concentration during the treatment cycle, and to avoid patient drug resistance caused by long-term uniform drug concentration; in another embodiment, an external magnetic navigation device can be used for navigation, percutaneous access to the drug storage chamber, and the drug can be re-implanted to achieve the purpose of long-term multiple drug delivery; in another embodiment, the local gradient magnetic field generated by the internal static magnetic field can accelerate tissue repair, and interact with the external magnetic component to facilitate surgical navigation positioning. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] In order to make the present invention more easily understood, the present invention will be described in more detail by referring to the specific embodiments shown in the accompanying drawings. These drawings only depict typical embodiments of the present invention and should not be considered as limiting the scope of protection of the present invention.

[0014] Figure 1 It is a front view of the first embodiment of the drug delivery system of the present invention.

[0015] Figure 2 It is a left side view of the first embodiment of the drug delivery system of the present invention.

[0016] Figure 3 It is a top view of a first embodiment of the drug delivery system of the present invention.

[0017] Figure 4 It is a rear view of the first embodiment of the drug delivery system of the present invention.

[0018] Figure 5 It is a bottom view of the first embodiment of the drug delivery system of the present invention.

[0019] Figure 6 It is a perspective view of a first embodiment of the drug delivery system of the present invention.

[0020] Figure 7 It is an isolated top view of a second embodiment of the drug delivery system of the present invention.

[0021] Figure 8 It is a front view of an isolated view of a second embodiment of the drug delivery system of the present invention.

[0022] Fig. 9 It is a left side view of an isolated view of a second embodiment of the drug delivery system of the present invention.

[0023] Fig.10 A perspective view of a second embodiment of the drug delivery system of the present invention from an isolated perspective.

[0024] Fig.11This is a perspective view of a drug delivery system according to another embodiment of the present invention from another perspective.

[0025] Fig.12 This is a perspective view of a second embodiment of the drug delivery system of the present invention from another isolated angle.

[0026] Fig.13 It is a cross-sectional view of a third embodiment of the drug delivery system of the present invention.

[0027] Fig.14 It is a cross-sectional perspective view of a third embodiment of the drug delivery system of the present invention.

[0028] Fig.15 It is a cross-sectional view of a fourth embodiment of the drug delivery system of the present invention.

[0029] Fig.16 It is a cross-sectional perspective view of a fourth embodiment of the drug delivery system of the present invention.

[0030] Fig.17 It is a cross-sectional view of a fifth embodiment of the drug delivery system of the present invention.

[0031] Fig.18 It is a cross-sectional perspective view of a fifth embodiment of the drug delivery system of the present invention.

[0032] Fig.19 It is a cross-sectional view of a sixth embodiment of the drug delivery system of the present invention.

[0033] Fig. 20 It is a cross-sectional perspective view of a sixth embodiment of the drug delivery system of the present invention.

[0034] Fig.21 It is a cross-sectional view of a seventh embodiment of the drug delivery system of the present invention.

[0035] Fig. 22 It is a cross-sectional perspective view of a seventh embodiment of the drug delivery system of the present invention.

[0036] Fig.23 A bottom view of the drug storage bin of the eighth embodiment of the drug delivery system of the present invention.

[0037] Fig.24 It is a perspective view of an eighth embodiment of the drug delivery system of the present invention.

[0038] Fig.25 It is a bottom view of the navigation device of the eighth embodiment of the drug delivery system of the present invention.

[0039] Fig.26 FIG. 1 is a top view of a navigation device of an eighth embodiment of a drug delivery system according to the present invention.

[0040] Fig. 27FIG. 1 is a perspective view from a top view of a navigation device of an eighth embodiment of a drug delivery system according to the present invention.

[0041] Fig.28 This is a perspective view from a bottom angle of a navigation device of an eighth embodiment of a drug delivery system according to the present invention.

[0042] Fig.29 An exploded view of a magnetic component of an eighth embodiment of the drug delivery system of the present invention at one angle.

[0043] Fig.30 This is an exploded view from another angle of the magnetic component of the eighth embodiment of the drug delivery system of the present invention.

[0044] Reference numerals

[0045] 1-drug delivery device; 11-drug storage chamber, 111-drug storage chamber mark; 13-drug sustained-release element; 14-drug channel, 141-first drug channel, 142-second drug channel, 143-third drug channel, 144-fourth drug channel; 145-blocking barrier element, 146-drug; 15-magnetic component, 151-housing, 152-ring magnet, 153-blocking barrier element; 16-navigation component channel, 161-blocking barrier element, 162-guiding component channel Navigation channel filling rod; 17-first magnetic component, 171-first shell, 172-first magnetic element, 173-first blocking element; 18-second magnetic component, 181-second shell, 182-second magnetic element, 183-second blocking element; 19-blocking element installation channel, 191-installation channel seal; 2-navigation device, 21-digital mark, 22-magnet, 23-drug loading navigation channel, 24-navigation positioning channel, 25-magnet. DETAILED DESCRIPTION

[0046] The following describes the implementation modes of the present invention with reference to the accompanying drawings so that those skilled in the art can better understand the present invention and implement it. However, the enumerated embodiments are not intended to limit the present invention. In the absence of conflict, the following embodiments and the technical features in the embodiments may be combined with each other, wherein the same components are represented by the same figure marks.

[0047] First embodiment

[0048] Figure 1-6 The first embodiment of the drug delivery system of the present invention is shown, and the system of the present invention comprises a drug delivery device 1 implanted in the human body, and a navigation device 2 located outside the human body. The navigation device 2 is used to navigate the drug delivery device 1 implanted in the human body.

[0049] like Figure 3As shown, the navigation device 2 is made of magnetic material or has a magnet embedded therein. In the embodiment shown in the figure, the navigation device 2 is shown in a disc shape, but it can also be in other shapes.

[0050] Specifically, the navigation device 2 has a navigation positioning channel 24, and a magnet 22 is arranged in the navigation positioning channel 24, and the magnet is preferably annular. The magnet 22 can exert force on the magnetic component in the navigation component channel 16 of the drug delivery device 1, so that the drug delivery device 1 and the navigation device 2 are attracted together. The navigation positioning channel 24 preferably runs through the navigation device 2. The navigation positioning channel 24 is preferably a stepped channel, and the aperture of the navigation positioning channel 24 is narrow at the top and wide at the bottom.

[0051] The navigation device 2 has a plurality of drug loading navigation channels 23. The drug loading navigation channels 23 pass through the navigation device 2. When the drug delivery device 1 and the navigation device 2 are attracted together, the drug loading navigation channels 23 can be coaxially and concentrically connected with the drug channel 14 of the corresponding drug storage bin of the drug delivery device 1, wherein the drug channel 14 passes from the top of the drug delivery device 1 all the way to the internal drug storage bin. Preferably, a magnet 25 is provided inside at least one drug loading navigation channel 23. Correspondingly, a magnetic component is installed in at least one drug channel 14, and the magnet 25 is used to attract the magnetic component. That is, the navigation positioning channel 24 serves as an axial positioning point, and the drug loading navigation channel 23 serves as another positioning point, so as to realize two-point or multi-point positioning.

[0052] A plurality of digital marks 21 (5 in the figure) are provided on the upper and / or lower surface of the navigation device 2. When the drug delivery device 1 and the navigation device 2 are attracted together, the digital marks 21 correspond one by one to the plurality of drug storage chambers of the drug delivery device 1. In this embodiment, the drug delivery device 1 may have one or more drug storage chambers, and five are shown in this example.

[0053] like Figure 4-7 As shown, the drug delivery device 1 is shown as a cylinder, and can also be other shapes. The drug delivery device 1 has a navigation component channel 16 in the center, and a magnetic component is arranged in the navigation component channel 16. The magnetic component can be attracted to the magnet 22 in the navigation positioning channel 24 of the navigation device 2, so that the drug delivery device 1 and the navigation device 2 are close to and attracted together. The navigation channel component 16 is preferably a stepped channel, which is narrow at the top and wide at the bottom. The magnetic navigation component is accommodated in the narrow upper channel, and a navigation channel filling rod 162 is arranged in the wide lower channel. The navigation channel filling rod 162 is used to block the navigation channel component 16 to prevent the magnetic component from escaping and to shield the magnetic field. The navigation channel filling rod 162 is preferably a hollow structure inside to reduce weight, and the material is bioceramics or the like.

[0054] The drug delivery device 1 has one or more drug channels 14, and the drug channels 14 lead from the top of the drug delivery device 1 to the respective drug storage bins 11, and the drug storage bins 11 are located inside the drug delivery device 1. A drug storage bin mark 111 is provided on the top surface of the drug delivery device 1 to mark each drug storage bin. Before the drug delivery device 1 is implanted in the human body, the drug in the drug storage bin 11 is injected or placed into the drug storage bin 11 through the drug channel 14 (the navigation device 2 is not required at this time). After the drug delivery device 1 is implanted in the human body, if the drug storage bin 11 needs to be added with drugs, the drug delivery device 1 is sucked close to the skin through the navigation device 2, and the two are matched together, and the drugs are passed through the drug channel 14 into the drug storage bin 11 through the register to achieve minimally invasive drug addition. The drug storage bin 11 can continuously release drugs, and there is no need to make a large incision to take out the drug delivery device 1 for adding drugs.

[0055] The drug delivery device 1 has one or more blocking element installation channels 19 on the side, which lead from the side to the respective drug storage bins 11 or drug channels 14. One or more drug sustained-release elements 13 are placed in the blocking element installation channels 19, and are sealed with installation channel seals 191. Sustained-release drugs can also be placed through the blocking element installation channels 19.

[0056] Second embodiment

[0057] Figure 9-12 A second embodiment of the drug delivery system of the present invention is shown. This embodiment differs from the first embodiment in that the magnetic component used comprises multiple elements.

[0058] Specifically, Fig.10 As shown, the drug delivery device 1 is a porous mesh structure and can be integrally formed by 3D printing.

[0059] The navigation component channel 16 is a stepped channel, which is narrow at the top and wide at the bottom. A blocking element 161 is arranged in the narrow channel at the top, and the blocking element 161 is used to seal the top opening of the navigation component channel 16. The blocking element 161 can be made of silicone and other soft materials. A first magnetic component 17 is arranged in the wide channel at the bottom of the navigation component channel 16. The navigation channel filling rod 162 is located below the first magnetic component 17. The first magnetic component 17 includes a first shell 171, a first magnetic element 172 and a first blocking element 173. The first magnetic element 172 is located in the first shell 171, and the first blocking element 173 is located below the first magnetic element 172.

[0060] Optionally, two magnetic components may be provided in the lower wide channel of the navigation component channel 16, such as Fig.10As shown, the first magnetic component 17 and the second magnetic component 18 are arranged in sequence from top to bottom. Among them, the second magnetic component 18 includes a second shell 181, a second magnetic element 182 and a second blocking barrier element 183. The second magnetic element 182 is located in the second shell 181, and the second blocking barrier element 183 is located above the second magnetic element 182. The two magnetic components can generate a changing magnetic field and a local gradient magnetic field. Preferably, the components of the first magnetic component 17 and the second magnetic component 18 are symmetrically arranged.

[0061] A drug channel magnetic component 15 (the magnetic component 15 has a hole in the center, preferably in an annular shape) is disposed on the upper portion of at least one drug channel 14 of the drug delivery device 1. The drug channel magnetic component 15 includes a housing 151, an annular magnet 152, and a blocking element 153. The annular magnet 152 is located in the housing 151, and the blocking element 153 is located above the annular magnet 152. Preferably, the magnetic component 15 can be magnetized or demagnetized.

[0062] A magnet 25 is provided in the drug loading navigation channel 23 on the navigation device 2, and the magnet 25 is used to attract the drug channel magnetic component 15 of the drug delivery device 1. The magnet 22 in the navigation positioning channel 24 of the navigation device 2 is used to attract the first magnetic component 17 and / or the second magnetic element 18 of the drug delivery device 1. Two attraction points are set to achieve two-point or multi-point positioning. At this time, the drug loading navigation channel 23 and the drug channel 14 are connected.

[0063] The drug delivery device 1 includes five separated drug storage bins 11, each of which can be used to store the same drug or different drugs, as required. Each drug storage bin 11 leads to the top of the drug delivery device 1 through a drug channel 14. When drugs need to be injected, the drug channel 14 is connected to the drug loading navigation channel 23 on the navigation device 2, and the syringe passes through the drug loading navigation channel 23 into the drug channel 14 to inject drugs, and the drugs finally enter the drug storage bin 11.

[0064] The drug delivery device 1 comprises transverse blocking element installation channels 19, each of which leads to the drug storage bin 11 or the drug channel 14. A plurality of drug sustained-release elements 191 can be loaded into the drug storage bin 11 or the drug channel 14 through the blocking element installation channels 19. The blocking element installation channels 19 are sealed by installation channel seals 191.

[0065] Third embodiment - straight hole continuous large amount of drug delivery

[0066] like Figure 13-14As shown, in this embodiment, the navigation positioning channel 24 of the navigation device 2 is stepped, narrow at the top and wide at the bottom, and the lower part contains the magnet 22. The drug loading navigation channel 23 of the navigation device 2 is stepped, narrow at the top and wide at the bottom, and the lower part contains the magnet 25, which is annular.

[0067] The drug channel 14 of the drug delivery device 1 is a straight hole channel, which can accept continuous large-scale drug delivery, and the drug enters the drug storage bin 11. The drug channel 14 includes a first drug channel 141 with a wide diameter at the top and a second drug channel 142 with a narrow diameter at the bottom. A magnetic component 15 is arranged inside the first drug channel 141. The magnetic component 15 is used to attract the magnet 25 in the drug loading navigation channel 23 of the navigation device 2, so that the first drug channel 141 and the drug loading navigation channel 23 are coaxial and concentric, and the positioning effect is achieved by the action of magnetic force. The top of the drug channel 14 has a blocking element 145 (preferably a silicone sleeve). In a preferred embodiment, the side wall of the drug sustained-release channel 14 is a porous mesh structure, that is, as long as the drug enters the drug channel 14, it begins to diffuse around. Sustained release is achieved by controlling the rate at which the drug inside the physical drug storage bin enters the sustained-release channel. Preferably, the drug storage bin part of the drug delivery device is solid, and the other parts are porous mesh structures, which can be formed by 3D printing.

[0068] Two magnetic components, a first magnetic component 17 and a second magnetic component 18 (the same as in the second embodiment), are arranged in the navigation component channel 16 , and the bottom of the channel is blocked by a navigation channel filling rod 162 .

[0069] Fourth embodiment - sliding ball reduced dose continuous drug delivery

[0070] like Figure 15-16 As shown, the main difference between this embodiment and the previous embodiment lies in the drug channel 14. In this embodiment, the drug channel 14 is a straight channel, including a second drug channel 142, a third drug channel 143, and a fourth drug channel 144 arranged in sequence from top to bottom. Among them, the diameter of the third drug channel 143 is larger than that of the second drug channel 142 and the fourth drug channel 144. A drug sustained-release element 13 is arranged in the third drug channel 143, and the drug sustained-release element 13 is a sliding ball, which can reduce the amount of continuous drug administration. The drug sustained-release element 13 can only slide up and down in the third drug channel 143. A blocking element installation channel 19 is connected to the third drug channel 143, and a channel filling rod (not shown) is arranged in the blocking element installation channel 19. The drug sustained-release element 13 can be loaded or removed through the blocking element installation channel 19. Through the drug sustained-release element 13, the drug in the drug storage bin 11 can be released more slowly through the drug channel 14 to achieve a sustained-release effect.

[0071] When in use, the drug is first injected into the drug storage chamber 11 through the drug channel 14, and then the drug sustained-release element 13 is placed through the blocking element installation channel 19, and then the installation channel seal 191 is inserted. After the drug delivery device 1 is implanted in the human body, with the movement of the joints at the implantation site, the small ball slides up and down in the large diameter area, achieving the purpose of reducing the amount of continuous drug delivery.

[0072] Fifth embodiment - intermittent drug administration with small hole outlet

[0073] like Figure 17-18 As shown, the main difference between this embodiment and the previous embodiment lies in the drug channel 14 and the drug storage bin 11. In this embodiment, the drug channel 14 is a straight channel, including a second drug channel 142 and a third drug channel 143. Among them, the diameter of the third drug channel 143 is larger than that of the second drug channel 142. One or more drugs 146 (shown as a balloon type in the figure) are arranged in the third drug channel 143. The initial diameter of the drug 146 is larger than the diameter of the third drug channel 143. The drug 146 is first degraded in the drug storage bin 11, and the drug enters the lesion through the drug channel 14. As the degradation continues, the diameter becomes smaller, and the drug 146 enters the third drug channel 143, and then enters the second drug channel 142 after continuous degradation. In this way, the time for the drug 146 to directly enter the lesion area is extended, and a longer sustained release effect is achieved.

[0074] The drug storage bin 11 is connected to a blocking element installation channel 19, and a channel filling rod (not shown) is arranged in the blocking element installation channel 19. The drug 146 can be loaded into the drug storage bin 11 through the blocking element installation channel 19, and then the channel filling rod (not shown) is inserted for blocking.

[0075] When multiple drugs 146 are placed, as the drug balloon in the large diameter channel degrades, the drugs enter the lesion area one by one, and the degradation rate of each balloon is controlled, thereby achieving the purpose of intermittent drug administration. If percutaneous drug implantation is required, navigation positioning can be used to inject the drug again from the side wall through the blocking element installation channel 19 with a needle.

[0076] Sixth embodiment - magnetic ball switch on-demand medication

[0077] like Figure 19-20 As shown, this embodiment is Figure 15-16The main difference of the fourth embodiment shown is that the drug release element 13 is magnetic. The drug channel 14 is a straight channel, including a second drug channel 142, a third drug channel 143, and a fourth drug channel 144 arranged in sequence from top to bottom. The drug release element 13 is magnetic, and an external magnetic field can be used to control drug release to achieve on-demand drug administration. The drug release element 13 enters the drug storage bin 11 through the blocking element installation channel 19, and the drug release element 13 can only slide up and down in the large diameter area of ​​the drug channel 14, that is, the third drug channel 143. When in use, the drug release element 13 initially keeps blocking the drug storage bin 11 (blocking the connection port of the third drug channel 143 to the second drug channel 142, and a depression can be set at the connection port so that the drug release element 13 can fall into the connection port more easily to block the channel), and the drug cannot be released through the drug channel 14. If a magnetic field is applied outside the patient's body, the drug release element 13 moves away from the channel port and moves to the side wall to achieve drug release, thereby achieving on-demand drug administration.

[0078] Seventh embodiment - Degradable drug sustained-release element controls delayed drug administration

[0079] like Figure 21-22 As shown, the main difference between this embodiment and the sixth embodiment lies in the blocking element installation channel 19. In this embodiment, the drug channel 14 is a straight channel, including a second drug channel 142 and a third drug channel 143. Among them, the diameter of the third drug channel 143 is larger than that of the second drug channel 142. One or more drug sustained-release elements 13 are arranged in the third drug channel 143, and the drug sustained-release element 13 can only slide in the third drug channel 143. The third drug channel 143 is connected to the blocking element installation channel 19, and a channel filling rod (not shown) is arranged in the blocking element installation channel 19. The drug sustained-release element 13 can be loaded or taken out through the blocking element installation channel 19. Through the drug sustained-release element 13, the drug in the drug storage bin 11 can be released more slowly through the drug channel 14 to achieve a sustained-release effect.

[0080] When in use, the drug is first injected into the drug storage chamber 11 through the drug channel 14, and then the drug sustained-release element 13 is placed through the blocking element installation channel 19, and then sealed with the installation channel seal 191 (the embodiment shown in the figure is a filling rod type, and it can also be a cap or cover). After the drug delivery device 1 is implanted in the human body, as the implanted part moves, the small ball slides up and down in the large diameter area, achieving the purpose of reducing the amount of continuous drug delivery. In addition, the material of the drug sustained-release element 13 is a degradable material (alloy, bioceramic, polymer material, etc.); as the drug sustained-release element 13 gradually degrades, the time of delayed drug delivery is controlled.

[0081] Eighth Embodiment

[0082] like Figure 23-28 As shown, in this embodiment, the drug delivery device 1 includes 5 drug storage bins, and correspondingly, the navigation device 2 includes 5 drug loading navigation channels 23. There are digital marks 21 on the upper and lower surfaces of the navigation device 2, which correspond to the drug storage bins inside the drug delivery device 1. The external navigation device 2 includes a stepped channel that runs from top to bottom, that is, a drug loading navigation channel 23, with a narrow aperture at the top and a wide aperture at the bottom. The navigation positioning channel 24 is a stepped channel, and the navigation positioning channel 24 is coaxially and concentrically connected with the drug channel 14 of the corresponding drug storage bin, and the navigation positioning channel 24 is coaxially and concentrically connected with the navigation component channel 16 of the drug delivery device 1. The stepped channel of the navigation positioning channel 24 contains an annular magnet 22. At least one drug loading navigation channel 23 contains an annular magnet 25. When in use, the navigation positioning channel 24 serves as an axial positioning point, and the drug loading navigation channel 23 serves as another positioning point to achieve two-point or multi-point positioning.

[0083] Ninth embodiment

[0084] like Figure 29-30 As shown, in this embodiment, the structure of the magnetic component 15 is shown. The magnetic component 15 includes a shell 151, an annular magnet 152 and a blocking element 152. The annular magnet 152 is located in the shell 151, and is sealed by the blocking element 152. The blocking element 152 is preferably made of silicone. When leaving the factory, it can be directly packaged into the magnetic component 15 as a standard unit for subsequent assembly. The annular magnet 152 is hollow in an annular shape, and the other components are made of silicone or other materials, ensuring that the syringe needle can pass through, so that the drug can be injected into the drug delivery chamber.

[0085] The targeted drug delivery device system of the present invention can be equipped with the required drugs in the drug storage bin according to the needs of the patient before use; then the appropriate degradation drug storage bin combination mode is selected according to the appropriate degradation cycle. After the in vitro assembly of the product is completed, the drug delivery device is implanted into the lesion area by surgical implantation, and the carried drugs are directly brought to the lesion, making full use of the drugs and directly acting on the lesions, thereby achieving the purpose of targeting. The drug delivery device of the present invention adopts a hierarchical regulation method to control the sustained release rate, and different combination modes can be adopted as needed to specifically regulate the timing of drug release from the drug storage bin. After a period of time, after the drug carried in the initial state of the system is released, the needle containing the target drug can be navigated by an external magnetic navigation device, percutaneously enter the drug storage bin, and the drug, stem cells, growth factors, hydrogels, etc. are implanted again to achieve the purpose of long-term multiple drug delivery. After the stent is implanted once, the drug can be implanted again and multiple times. The internal annular magnet can generate a local high-intensity gradient magnetic field, which can adsorb magnetic nano drug-loaded microspheres directly to the lesion, interact with the externally applied magnetic field, and further activate and promote the repair of the tissue at the lesion.

[0086] In the third embodiment, the drug channel of the drug storage bin is not provided with a blocking element, and the drug is released directly.

[0087] In the fourth embodiment, a drug sustained-release element is disposed on the top of the sustained-release channel of the drug storage bin. With the movement of the joint of the implanted part, the drug sustained-release element can move up and down, thereby achieving the purpose of continuous drug administration with reduced dosage.

[0088] In the fifth embodiment, drug-loaded microspheres and small balls are placed inside the drug storage compartment, and their initial diameter is larger than the diameter of the drug channel. As the coating material on the surface of the microspheres degrades, they gradually reach the lesion area along the drug channel, thereby achieving intermittent drug administration.

[0089] In the sixth embodiment, a magnetic blocking element is provided in the drug storage compartment. Under normal conditions, the small ball blocks the drug channel. When medication is needed, a magnetic field is applied outside the patient's lesion site, and the small ball moves to the side wall. The drug channel maintains the channel to achieve medication, thereby achieving the effect of medication at any time as needed.

[0090] In the seventh embodiment, the drug channel of the drug storage chamber is a stepped hole with a large diameter at the top of the drug storage chamber, and a degradable drug sustained-release element (alloy, bioceramic, polymer material) of matching diameter is placed inside. The degradation cycle is controlled by the number and volume of the small balls, thereby achieving the purpose of delayed or intermittent administration.

[0091] The five types of drug storage bins can be freely matched, and the number of drug storage bins can be set as needed; under normal circumstances, the drug sustained-release rate comparison is: the drug storage bin of the third embodiment < the drug storage bin of the fourth embodiment < the drug storage bin of the fifth embodiment < the drug storage bin of the sixth embodiment < the drug storage bin of the seventh embodiment.

[0092] The targeted drug delivery device system of the present invention can realize flow control and control the magnitude of drug sustained-release flow through different drug storage bin combinations.

[0093] The targeted drug delivery device system of the present invention can achieve phased drug delivery. In the short term, this can be achieved by equipping different drug storage chamber combinations; long-term phased drug delivery can be achieved by equipping the drug storage chambers with different numbers of drug sustained-release elements.

[0094] The targeted drug delivery device system of the present invention can utilize a static magnetic field. The implanted components are equipped with magnets, which can adsorb magnetic nano-drug-loaded microspheres and small balls directly to the lesions. Through combination and arrangement, the purpose of generating a local gradient magnetic field can be achieved to promote tissue repair. At the same time, the internal magnetic field is also the navigation source of the external magnetic navigation device.

[0095] The targeted drug delivery device system of the present invention can achieve targeted drug delivery. By surgical implantation, the repair system is directly implanted into the lesion area, the carried drugs are directly delivered, the drugs are fully utilized, and directly act on the lesions, thereby achieving the purpose of targeting.

[0096] The targeted drug delivery device system of the present invention can realize percutaneous drug reimplantation. After a period of time, when the drug carried by the system in the initial state is released, the needle containing the target drug can be navigated by an external magnetic navigation device, percutaneously enter the drug storage chamber, and the drug is re-implanted, thereby achieving the purpose of long-term and multiple drug delivery. Once implanted, the drug can be implanted again for life.

[0097] The targeted drug delivery device system of the present invention is convenient for navigation and positioning, contains a magnet inside, and an external magnetic navigation device interacts with the internal magnetic field to achieve two-point or multi-point positioning, thereby achieving the purpose of navigation and positioning.

[0098] The embodiments described above are only preferred specific implementations of the present invention. This specification uses the phrases "in one embodiment", "in another embodiment", "in yet another embodiment" or "in other embodiments" to refer to one or more of the same or different embodiments according to the present disclosure. Common changes and substitutions made by those skilled in the art within the scope of the technical solution of the present invention should be included in the protection scope of the present invention.

Claims

1. A targeted drug delivery device, characterized in that: include: A drug storage chamber (11), located inside the targeted drug delivery device; a drug channel (14), the drug channel (14) leading from the surface of the targeted drug delivery device to the drug storage bin (11), comprising a second drug channel (142), a third drug channel (143) and a fourth drug channel (144), the second drug channel (142) leading to the surface of the targeted drug delivery device, the third drug channel (143) being located between the second drug channel (142) and the fourth drug channel (144) and having a larger diameter than the second drug channel (142) and the fourth drug channel (144), and the fourth drug channel (144) leading to the drug storage bin (11); The drug sustained-release element (13) slides up and down in the third drug channel (143) and is used to enable the drug in the drug storage chamber (11) to be slowly released through the drug channel (14).

2. The targeted drug delivery device according to claim 1, characterized in that: Also includes: The blocking element installation channel (19) is connected to the third drug channel (143), and the drug sustained-release element (13) is loaded or removed through the blocking element installation channel (19). A mounting channel seal (191) is provided, which is used to seal the blocking element mounting channel (19).

3. The targeted drug delivery device according to claim 1, characterized in that: The drug sustained-release element (13) has magnetism and is made of a degradable material.

4. The targeted drug delivery device according to claim 1, characterized in that: The side wall of the drug channel (14) is a porous mesh structure.

5. A targeted drug delivery system, characterized in that: include: The drug delivery device (1) according to any one of claims 1 to 4, wherein the drug delivery device (1) further comprises: a navigation component channel (16) having a magnetic component disposed therein; The navigation device (2) comprises: a navigation positioning channel (24) having a magnet disposed therein, wherein the magnet of the navigation positioning channel (24) is capable of being attracted to a magnetic component in the navigation component channel (16); and a drug loading navigation channel (23), wherein when the navigation device (2) and the drug delivery device (1) are attracted together, the drug loading navigation channel (23) is connected to the drug delivery channel (14) of the drug delivery device (1).

Images